What is SS-31 in research contexts?

SS-31 (elamipretide) is a synthetic four-amino-acid Szeto-Schiller tetrapeptide that selectively binds cardiolipin in the inner mitochondrial membrane. It is studied in preclinical research for cristae stabilization, mitochondrial bioenergetics, and ischemia-reperfusion injury.

How do SS-31 and MOTS-c differ mechanistically?

SS-31 is a cardiolipin-binding tetrapeptide that physically stabilizes mitochondrial inner membrane structure. MOTS-c is a mitochondrial-derived peptide that signals through AMPK activation to drive metabolic adaptations. Both target mitochondria but through fundamentally different mechanisms.

Which peptide is preferred for which research applications?

SS-31 is preferred for membrane integrity research, ischemia-reperfusion protection, and mitochondrial dysfunction in disease and aging. MOTS-c is preferred for metabolic regulation research, exercise mimetic studies, and AMPK pathway activation. Combination research explores complementary effects.

Is SS-31 approved for human use?

No. SS-31 is not approved by the FDA for any human therapeutic use. It is supplied strictly for in-vitro and preclinical research purposes by qualified investigators.

Where can researchers source third-party tested SS-31?

Midwest Peptide supplies research-grade SS-31 with a Certificate of Analysis included for every batch, validated by HPLC purity and mass spectrometry identity testing.

SS-31 vs MOTS-C: Mito Peptide Comparison

Age Verification

You must be 21 years or older to access this website. All products are for research use only.

Are you 21 years of age or older?

By entering, you confirm that you are at least 21 years old and agree to our terms of service.

Free shipping on every orderFree shipping on every order

5% off when you pay with ZelleSave an extra 5% when you pay with Zelle

Bulk pricing discounts up to 18%Bulk pricing discounts up to 18% off

SS-31 vs MOTS-C: Mito Peptide Comparison | Midwest Peptide

For Research Use Only. SS-31 and MOTS-C are intended exclusively for in vitro and preclinical research. Neither compound is approved for human use, neither is a drug, and neither should be administered to humans or to animals outside of an authorized research protocol.

Why Researchers Compare SS-31 and MOTS-C

The two compounds are the most cited mitochondrial-targeted research peptides in the published literature, and the comparison question reflects the practical reality that researchers working on mitochondrial biology often need to choose between them or decide whether to pair them. Both compounds have substantial published preclinical literature, both are commercially available as research-grade reference material, and both are frequently used as comparator arms in mitochondrial research designs. The comparison literature documents the distinct mechanisms, the typical application areas, and the cases where one compound is preferred over the other.

The published comparisons fall into two categories. Head-to-head designs administer the compounds individually and compare endpoints in matched experimental conditions. Combination designs administer both compounds together and compare the combined arm with each compound alone, characterizing additive or synergistic effects on integrated mitochondrial endpoints. Both design types contribute to the comparison literature.

Mechanism Comparison: Membrane Protection Versus Metabolic Signaling

The most fundamental distinction between SS-31 and MOTS-C is mechanism of action. SS-31 is a synthetic Szeto-Schiller tetrapeptide that selectively concentrates in the inner mitochondrial membrane through cardiolipin binding, with the protective effect anchored at the membrane surface where ROS production and respiratory chain assembly occur. The mechanism is structural and operates by stabilizing the physical organization of the mitochondrial inner membrane under stress conditions. For an extended discussion of the SS-31 mechanism, see our companion article on SS-31 mechanism of action and cardiolipin binding research.

MOTS-C by contrast is a 16-amino-acid mitochondrially encoded peptide that acts as a metabolic signaling molecule rather than a direct membrane stabilizer. The mechanism is generally described in terms of AMPK activation, modulation of methionine and folate metabolism, and broader effects on metabolic gene expression. MOTS-C effects are signaling-mediated and operate through transcriptional and metabolic pathways rather than through direct membrane interactions. The mechanism distinction matters because it predicts where each compound will have its largest individual effects.

The Nature subject hub on mitochondria and the ScienceDirect topic page on AMPK archive primary research on the mechanism distinctions.

Subcellular Localization and Targeting

SS-31 selectively concentrates in the inner mitochondrial membrane through cardiolipin binding, with concentration ratios between mitochondria and cytoplasm reaching multiple orders of magnitude in published research. The targeting is direct and structural, with the peptide accumulating where the cardiolipin substrate is located. MOTS-C by contrast distributes more broadly, with effects on mitochondrial gene expression, on cytoplasmic AMPK signaling, and on nuclear transcriptional programs. The distribution pattern reflects the signaling mechanism rather than direct mitochondrial targeting.

The localization distinction influences research design decisions. Studies that need to maximize mitochondrial peptide content for direct membrane effects favor SS-31. Studies that need to engage broader metabolic signaling pathways favor MOTS-C. Studies that aim to engage both layers of mitochondrial biology benefit from combination designs.

Functional Endpoint Comparison

Across the published comparison literature, distinct endpoint profiles emerge for the two compounds. SS-31 produces larger effects on endpoints that emphasize mitochondrial structural integrity, cristae architecture, supercomplex assembly, and direct ROS production rates. MOTS-C produces larger effects on endpoints that emphasize metabolic regulation, AMPK activation downstream targets, glucose homeostasis, and metabolic gene expression profiles. The endpoint differences reflect the mechanism differences and inform research design decisions about which endpoints to prioritize when choosing between the compounds.

Both compounds produce effects on many shared endpoints (overall mitochondrial respiration, ATP synthesis under stress, oxidative damage markers), with the magnitude and consistency varying based on the experimental model and stress context. Research designs that include endpoints aligned with the mechanism of each compound generate more interpretable comparative data than designs that use generic endpoints alone.

The Cell Press journal Cell Metabolism archives primary research on mitochondrial metabolism relevant to the comparison literature.

Aging and Mitochondrial Decline Comparison

Both SS-31 and MOTS-C have been examined in aging research models, where the mitochondrial decline framework predicts that interventions which preserve or restore mitochondrial function should benefit aged tissue. The published comparison literature in aging models documents distinct profiles for the two compounds. SS-31 effects in aged tissue emphasize preserved cristae architecture, maintained respiratory chain organization, and reduced ROS production from the structurally protected mitochondria. MOTS-C effects in aged tissue emphasize restored AMPK signaling, improved metabolic flexibility, and beneficial effects on age-associated metabolic dysfunction.

For an extended discussion of the SS-31 aging research specifically, see our companion article on SS-31 aging research and mitochondrial decline studies. The aging framework also overlaps with NAD+ longevity studies since multiple mitochondrial-targeted research compounds engage related aspects of the aging biology.

Cardiac Research Comparison

Cardiac research is one of the highest-volume areas in the mitochondrial peptide literature, particularly for ischemia-reperfusion injury models. The published comparison work documents that SS-31 produces particularly strong effects on cardiac ischemia-reperfusion endpoints because the mechanism (cardiolipin protection, cristae stabilization, mPTP attenuation) is mechanistically aligned with the injury biology. MOTS-C effects in cardiac models emphasize the metabolic dimension and the broader signaling effects on cardiomyocyte function. Both compounds produce protective effects, but the magnitude and the specific endpoints differ in ways that reflect the mechanism differences.

For an extended discussion of the SS-31 cardiac research, see our companion article on SS-31 cardiac research and ischemia-reperfusion studies.

The Frontiers in Physiology cardiac section archives primary research on cardiac mitochondrial biology relevant to the comparison.

Metabolic and Glucose Homeostasis Research

In metabolic research, MOTS-C has the larger published literature because the mechanism is directly aligned with metabolic regulation through AMPK activation and downstream metabolic gene expression. Documented MOTS-C effects in metabolic models include improved glucose homeostasis, reduced insulin resistance markers, and altered metabolic flexibility in animal-model studies. SS-31 has a smaller metabolic literature, with the metabolic effects generally framed as downstream consequences of preserved mitochondrial function rather than direct metabolic regulation.

For research designs focused on metabolic endpoints, the mechanism alignment favors MOTS-C as the primary compound. For research designs focused on mitochondrial structural protection with metabolic endpoints as secondary outcomes, SS-31 is appropriate. The mechanism-aligned design choice produces more informative comparative data than picking either compound by default.

Pharmacokinetic Differences

The pharmacokinetic profiles of SS-31 and MOTS-C differ in ways that influence research design. SS-31 shows selective mitochondrial accumulation through cardiolipin binding, with high mitochondrial concentration ratios that allow effective dosing at relatively low overall exposure levels. MOTS-C shows broader cellular distribution with effects on multiple compartments, requiring different exposure considerations for the metabolic signaling effects. Pharmacokinetic comparison data in the public literature is incomplete for both compounds, which is itself a finding in the comparison literature.

Research programs that include pharmacokinetic characterization with their efficacy designs contribute particularly informative work because they connect exposure to endpoint outcomes in a way that purely outcome-focused studies cannot.

Combination Research: When Both Are Used Together

The complementary mechanisms of SS-31 and MOTS-C are why combination research is a growing area in the mitochondrial peptide literature. Combination designs administer both compounds together and compare the combined arm with each compound alone. The mechanistic prediction is that the combination engages both the structural protection layer (SS-31) and the metabolic signaling layer (MOTS-C), producing effects that exceed what either compound delivers alone for endpoints that depend on both layers.

Published combination work documents additive effects on most mitochondrial endpoints, with selected endpoints showing synergistic profiles where the combined effect exceeds the sum of individual effects. Endpoints that integrate structural and metabolic dimensions (overall respiratory capacity in stressed tissue, integrated functional outcomes in aging models) tend to show synergy. Endpoints specific to one mechanism dimension show additivity.

The Wiley Online Library mitochondrial research collection archives primary research on combination mitochondrial biology relevant to the SS-31 plus MOTS-C literature.

Cross-Cluster Context: NAD+ and Glutathione

In the broader mitochondrial research landscape, SS-31 and MOTS-C are two of several research compounds that engage related biology through different mechanisms. The NAD+ research cluster covers the central coenzyme of mitochondrial metabolism that operates through redox cycling and substrate availability for sirtuin and PARP enzymes. The glutathione research cluster covers the master antioxidant tripeptide that operates in cytoplasm and mitochondria through a redox mechanism distinct from membrane stabilization.

Each research compound in the broader landscape contributes a distinct mechanism vector to mitochondrial biology research. Programs that include multiple compounds in their inventory and that select compounds based on mechanism alignment with research questions generate more interpretable cumulative data than programs that pick one compound by default for all designs.

How to Choose Between Them in a Research Design

For research designs that need to choose between SS-31 and MOTS-C, the practical guidance from the comparison literature is to align the choice with the mechanism the design is studying. Mitochondrial structural endpoints (cristae architecture, supercomplex assembly, direct ROS production rates) favor SS-31. Metabolic endpoints (AMPK signaling, glucose homeostasis, metabolic gene expression) favor MOTS-C. Cardiac ischemia-reperfusion designs favor SS-31 because of the mechanism alignment with the injury biology. Aging and metabolic decline designs can use either compound depending on which mechanistic dimension the research emphasizes.

For research designs that span multiple mechanistic domains, the combination design is often preferable to choosing between them. The choice should also consider the existing literature on the specific endpoint being studied; if most published work in a specific area uses one compound rather than the other, replicating with the same compound improves comparability with the existing literature.

Sourcing for Comparison Research

Comparison research is most reliable when both compounds are supplied with documented identity and purity. Research that uses well-characterized research-grade material with third-party COA documentation produces more reliable head-to-head data than research using commercial material lacking complete documentation. Comparison itself is meaningless if either compound is impure or contains material that does not match the labeled identity.

SS-31 10mg and MOTS-C 10mg supplied by Midwest Peptide are provided with third-party COA documentation as research-grade reference compounds. For sourcing details on SS-31 specifically, see our companion article on where to buy SS-31 for research and the elamipretide sourcing guide.

Open Questions in Comparison Research

Several open questions remain in the SS-31 versus MOTS-C comparison literature. The optimal combination ratio and dosing schedule for combination research is incompletely characterized in the public literature. Pharmacokinetic head-to-head data is limited, particularly across different species and routes of administration. The mechanism boundary between the compounds is also incompletely defined for endpoints that integrate structural and metabolic dimensions, since both compounds influence multiple downstream pathways.

These open questions create opportunities for new comparison research that contributes to the cumulative literature. Research programs that include head-to-head and combination arms in the same design generate the most informative data because they characterize the individual and combined contributions in matched experimental conditions.

Research Peptides Referenced

SS-31 10mg, research grade Szeto-Schiller mitochondrially targeted tetrapeptide
MOTS-C 10mg, mitochondrially encoded peptide for metabolic and aging research
NAD+ 500mg, central coenzyme of mitochondrial metabolism
Glutathione 1500mg, master antioxidant for mitochondrial redox research

For complete sourcing details see the SS-31 sourcing guide.

Within the SS-31 cluster:

Related clusters:

Not for human consumption. Research use only.

Age Verification

SS-31 vs MOTS-C: Mitochondrial Peptide Comparison Research

Frequently Asked Questions

What is SS-31 in research contexts?

How do SS-31 and MOTS-c differ mechanistically?

Which peptide is preferred for which research applications?

Is SS-31 approved for human use?

Glossary

More from the Blog

Subcutaneous vs Intranasal: Choosing an Administration Route for DSIP, Selank, and Kisspeptin in Research

Can I Still Buy Compounded Tirzepatide? (2026 Research Context)

Why Researchers Compare SS-31 and MOTS-C

Mechanism Comparison: Membrane Protection Versus Metabolic Signaling

Subcellular Localization and Targeting

Functional Endpoint Comparison

Aging and Mitochondrial Decline Comparison

Cardiac Research Comparison

Metabolic and Glucose Homeostasis Research

Pharmacokinetic Differences

Combination Research: When Both Are Used Together

Cross-Cluster Context: NAD+ and Glutathione

How to Choose Between Them in a Research Design

Sourcing for Comparison Research

Open Questions in Comparison Research

Research Peptides Referenced

Ready to Start Your Research?

Where can researchers source third-party tested SS-31?

What's the Cheapest Way to Get Tirzepatide (GLP-2 TZ) for Research?

Age Verification

SS-31 vs MOTS-C: Mitochondrial Peptide Comparison Research

Frequently Asked Questions

What is SS-31 in research contexts?

How do SS-31 and MOTS-c differ mechanistically?

Which peptide is preferred for which research applications?

Is SS-31 approved for human use?

Glossary

More from the Blog

Subcutaneous vs Intranasal: Choosing an Administration Route for DSIP, Selank, and Kisspeptin in Research

Can I Still Buy Compounded Tirzepatide? (2026 Research Context)

Why Researchers Compare SS-31 and MOTS-C

Mechanism Comparison: Membrane Protection Versus Metabolic Signaling

Subcellular Localization and Targeting

Functional Endpoint Comparison

Aging and Mitochondrial Decline Comparison

Cardiac Research Comparison

Metabolic and Glucose Homeostasis Research

Pharmacokinetic Differences

Combination Research: When Both Are Used Together

Cross-Cluster Context: NAD+ and Glutathione

How to Choose Between Them in a Research Design

Sourcing for Comparison Research

Open Questions in Comparison Research

Research Peptides Referenced

Related Research Reading

Ready to Start Your Research?

Where can researchers source third-party tested SS-31?

What's the Cheapest Way to Get Tirzepatide (GLP-2 TZ) for Research?